of data
support
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
2-Cyno Ethisterone
● In Stock
| Catalogue No.: | VE0025317 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C22H27NO2 |
| Mol. Weight: | 337.46 g/mol |
Additional information on 2-Cyno Ethisterone
Parent drug
NorethisteroneIUPAC Name
(10R, 13S, 17R)-17-ethynyl-17-hydroxy-10, 13-dimethyl-3-oxo-2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthrene-2-carbonitrilePharmacopoeial Synonyms
N/AOther Synonyms
N/ASmiles
N#CC1C(C=C(CCC2C3CC[C@@]4(C)C2CC[C@]4(C#C)O)[C@]3(C)C1)=OInChI
InChI=1S/C22H27NO2/c1-4-22(25)10-8-18-16-6-5-15-11-19(24)14(13-23)12-20(15, 2)17(16)7-9-21(18, 22)3/h1, 11, 14, 16-18, 25H, 5-10, 12H2, 2-3H3/t14?, 16?, 17?, 18?, 20-, 21-, 22-/m0/s1Description
2-Cyno Ethisterone impurity is a structurally related byproduct arising from incomplete reduction or inadvertent cyanomethylation during steroidal ethisterone synthesis. It presents specific analytical challenges due to close retention characteristics and similar mass spectral fragments to the parent API | necessitating orthogonal methods such as reversed phase HPLC with UV and LC-MS confirmation | high resolution mass spectrometry and 1H and 13C NMR for unambiguous identification. Risk assessment should address formation pathways | stability under forced degradation | solubility and polymorphism effects | and potential impact on pharmacopoeial specifications. A robust control strategy including process optimization | in-process monitoring and validated impurity limits aligned with ICH guidance is recommended.
Request a Quote
"*" indicates required fields